Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (101-110 of 191) with videos related to

Pageof 20
Sort By:
Immunology|September 16, 2005
Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogensKaren Scott, Maria Manunta, Conrad Germain, et al.
Annals of Gastroenterology|May 5, 2017
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational studyAlessandra Mangia, Graham R Foster, Christoph P Berg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsZobair M Younossi, Maria Stepanova, Mark Sulkowski, et al.
Hepatology (Baltimore, Md.)|April 5, 2013
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin, Peter Vickerman, Jason Grebely, et al.
Journal of Hepatology|May 5, 2004
Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trialsAlessandra Mangia, Gioacchino Leandro, Beat Helbling, et al.
Journal of Thrombosis and Haemostasis : JTH|September 13, 2024
The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of HemophiliaVincenzo La Mura, Massimo Colombo, Graham R Foster, et al.
Frontiers in Medicine|May 14, 2021
Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UKNaheed Choudhry, Kate Drysdale, Carla Usai, et al.
Clinical Medicine (London, England)|June 3, 2016
Randomised controlled trial of GP-led in-hospital management of homeless people ('Pathway')Nigel Hewett, Peter Buchman, Jeflyn Musariri, et al.
Annals of Surgery|May 29, 2015
Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5Rajiv Lahiri, Yannick Derwa, Zora Bashir, et al.
Journal of Gastroenterology|March 15, 2019
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionAtsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, et al.
Pageof 20

Showing results (101-110 of 191) with videos related to

Sort By:
Pageof 20
Immunology|September 16, 2005
Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogensKaren Scott, Maria Manunta, Conrad Germain, et al.
Annals of Gastroenterology|May 5, 2017
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational studyAlessandra Mangia, Graham R Foster, Christoph P Berg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsZobair M Younossi, Maria Stepanova, Mark Sulkowski, et al.
Hepatology (Baltimore, Md.)|April 5, 2013
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin, Peter Vickerman, Jason Grebely, et al.
Journal of Hepatology|May 5, 2004
Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trialsAlessandra Mangia, Gioacchino Leandro, Beat Helbling, et al.
Journal of Thrombosis and Haemostasis : JTH|September 13, 2024
The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of HemophiliaVincenzo La Mura, Massimo Colombo, Graham R Foster, et al.
Frontiers in Medicine|May 14, 2021
Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UKNaheed Choudhry, Kate Drysdale, Carla Usai, et al.
Clinical Medicine (London, England)|June 3, 2016
Randomised controlled trial of GP-led in-hospital management of homeless people ('Pathway')Nigel Hewett, Peter Buchman, Jeflyn Musariri, et al.
Annals of Surgery|May 29, 2015
Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5Rajiv Lahiri, Yannick Derwa, Zora Bashir, et al.
Journal of Gastroenterology|March 15, 2019
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infectionAtsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, et al.
Pageof 20